Michael Nall has over 25 years of healthcare experience, with the past 18 in cancer genomics. He has served as President and CEO of Biocept for the past 4 years, leading the company from R and D stage to a fully commercialized entity. Prior to Biocept, Michael was the General Manager, North America Sales and Marketing at Clarient, under the GE Healthcare umbrella, leading all facets of commercial operations and reimbursement. He started at Clarient prior to the beginning of the lab in 2002, integrated the business into GE and was recruited by the board to join Biocept in 2013. Other companies where Michael has served include Impath, Maquet Surgical, American Cyanamid and Horizon. Michael earned a Bachelors Degree in Business Administration from University of Central Missouri.
Clinical Dx Showcase: Biocept, Inc.
Biocept is a leader in the liquid biopsy space delivering personalized results for cancer patients, from a simple blood sample.
Liquid Biopsy – Why It Matters
Biocept’s Target Selector liquid biopsy offering is helping patients diagnosed with cancer and their physicians gain a more complete understanding of treatment options. We will share data gained from over 14,000 patient samples with results gained from CTCs and ctDNA which have been analyzed for expression, fusions, deletions, mutations and copy number variation. This testing is a complement to tissue-based testing in order to insure a patient is given the chance to qualify for targeted therapy. In addition, liquid biopsy offers the option to monitor for effectiveness of therapy in real-time by providing quantitative results that can be trended over various time points.